Delta Air Lines Inc. on Wednesday said it sees an opportunity to tap into affluent travelers as it laid out its long-term goals the next three-to-five years.
It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease.
The chances of another rate cut this year by the Bank of England has diminished after data showed an acceleration in the pace of Britain’s inflation last month.